Reason: Registry status: TERMINATED
Stage at discontinuation: phase_2
The most recent ClinicalTrials.gov query no longer returns this candidate — usually because every trial grouped under it has completed, so it has dropped out of the active-status search. The record below is kept as it stood at the fetch of 2026-07-10 and has not been re-confirmed since. Check the linked trials directly for their current state.
Explore licensed vaccines, adverse event reporting data, and history for this disease.
Development discontinued.
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Not Filed / Pre-submission |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Discontinued or withdrawn; tracked, not projected.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Stopped at Phase 2
Discontinued. No adoption window is projected for a stopped programme.
Scientific Profile & Documentation
- Platform Architecture
- Biological (unspecified platform)
- Lead Developer
- Takeda
- Next Expected Milestone
- Primary completion (most advanced trial): 2018-04-03 (registry estimate)
- Analyst & Development Notes
- Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
- Primary Source Documentation
- ClinicalTrials.gov NCT03092791 →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults
Milestone Overview
-
Stage VerificationDiscontinued / Inactive confirmed as of 2026-07-10.
-
Target MilestonePrimary completion (most advanced trial): 2018-04-03 (registry estimate)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.